ICH

International Council for Harmonisation

InternationalInternationalInternational harmonizer

Harmonizes technical requirements (Q, E, M series) adopted by regulators worldwide.

Browse the standards library →Official site ↗

WHAT ICH COVERS

The International Council for Harmonisation brings regulators and industry together to develop harmonised technical guidelines for pharmaceutical development, manufacturing, and registration. Its output is organised in four series: Quality (Q), Safety (S), Efficacy (E), and Multidisciplinary (M) — with the Q series carrying most of what GxP practitioners work with daily.

WHERE IT SITS INTERNATIONALLY

ICH membership spans the major regulators — FDA, EMA, PMDA, Health Canada, MHRA, Swissmedic, NMPA, ANVISA, MFDS and others — which is precisely why its guidelines function as the global technical baseline.

HOW ITS REQUIREMENTS BITE

ICH does not inspect or enforce anything. Its guidelines acquire legal force only when a regional regulator adopts them — as the EU does by publishing them in EudraLex, and as FDA does by issuing them as guidance. That adoption step is why the same ICH guideline can be in force in one market and not yet in another.

WHAT ICH PUBLISHES

  1. 01Q series — quality (Q1 stability, Q2 analytical validation, Q5 biotech, Q7 API GMP, Q8–Q12 development, risk, quality systems, and lifecycle)
  2. 02S series — non-clinical safety
  3. 03E series — efficacy and clinical, including E6 Good Clinical Practice
  4. 04M series — multidisciplinary, including MedDRA and the CTD format
  5. 05Q&As and training material that often carry the practical interpretation

WHAT PRACTITIONERS GET WRONG

  • An ICH guideline is not law until a regulator adopts it — check the status in each market you supply.
  • Q8(R2), Q9(R1), Q10, Q11 and Q12 function as an integrated set; reading one without the others gives a partial picture.
  • The CTD format (M4) is why a single dossier structure works across regions.
  • Revisions matter: Q9(R1) and E6(R3) changed expectations materially over their predecessors.

ICH STANDARDS SPEQ DECODES · 12

ICH Q5A(R2)
Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
ICH Q9(R1)
Quality Risk Management
ICH Q10
Pharmaceutical Quality System
ICH Q8(R2)
Pharmaceutical Development
ICH Q11
Development and Manufacture of Drug Substances (Chemical and Biotechnological/Biological Entities)
ICH Q12
Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q7
Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
ICH E6(R3)HIGH INSPECTION RISK
Good Clinical Practice (GCP)
ICH E8(R1)
General Considerations for Clinical Studies
ICH E2B(R3)
Electronic Transmission of Individual Case Safety Reports (ICSRs)
ICH E2A
Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
ICH Q3D(R2)
Guideline for Elemental Impurities

DISCIPLINES IN ICH’S REMIT

GMPGood Manufacturing PracticeGCPGood Clinical PracticeGVPGood Pharmacovigilance Practice
Weekly Briefing

Track ICH — and every regulator that matters

New rules, guidance, enforcement, and inspection signals from International Council for Harmonisation and its peers worldwide, distilled into the free Weekly GxP Briefing.

Read a past issue →